Literature DB >> 23809878

Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6.

Edith Hintermann1, Janine Ehser, Monika Bayer, Josef M Pfeilschifter, Urs Christen.   

Abstract

Autoimmune hepatitis type 2 (AIH-2) is a severe autoimmune liver disease with unknown etiology. We recently developed the CYP2D6 mouse model for AIH-2, in which mice are challenged with an adenovirus (Ad-2D6) expressing human cytochrome P450 2D6 (hCYP2D6), the major autoantigen in AIH-2. Such mice develop chronic hepatitis with cellular infiltrations and generation of hCYP2D6-specific antibodies and T cells. Importantly, the CYP2D6 model represents the only model displaying chronic fibrosis allowing for a detailed investigation of the mechanisms of chronic autoimmune-mediated liver fibrogenesis. We found that hCYP2D6-dependent chronic activation of hepatic stellate cells (HSC) resulted in an increased extracellular matrix deposition and elevated expression of α-smooth muscle actin predominantly in and underneath the liver capsule. The route of Ad-2D6 infection dramatically influenced the activation and trafficking of inflammatory monocytes, NK cells and hCYP2D6-specific T cells. Intraperitoneal Ad-2D6 infection caused subcapsular fibrosis and persistent clustering of inflammatory monocytes. In contrast, intravenous infection caused an accumulation of hCYP2D6-specific CD4 T cells throughout the liver parenchyma and induced a strong NK cell response preventing chronic HSC activation and fibrosis. In summary, we found that the location of the initial site of inflammation and autoantigen expression caused a differential cellular trafficking and activation and thereby determined the outcome of AIH-2-like hepatic damage and fibrosis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AIH; Ad; Adenoviral vectors; Autoimmune hepatitis; CCl(4); CYP2D6; Cytochrome P450; ECM; Fibrosis; HSC; LKM-1; Liver immunology; PBC; PSC; adenovirus; autoimmune hepatitis; carbon tetrachloride; extracellular matrix; hepatic stellate cell; human Cytochrome P450 2D6; liver-kidney-microsomal type 1; primary biliary cirrhosis; primary sclerosing cholangitis; α-smooth muscle actin; αSMA

Mesh:

Substances:

Year:  2013        PMID: 23809878     DOI: 10.1016/j.jaut.2013.05.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  12 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Pathogens and autoimmune hepatitis.

Authors:  U Christen; E Hintermann
Journal:  Clin Exp Immunol       Date:  2018-10-07       Impact factor: 4.330

Review 3.  Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis.

Authors:  Muhammed Yüksel; Debby Laukens; Femke Heindryckx; Hans Van Vlierberghe; Anja Geerts; F Susan Wong; Li Wen; Isabelle Colle
Journal:  Int J Exp Pathol       Date:  2014-08-12       Impact factor: 1.925

4.  Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease.

Authors:  Zhaolian Bian; Qi Miao; Wei Zhong; Haiyan Zhang; Qixia Wang; Yanshen Peng; Xiaoyu Chen; Canjie Guo; Li Shen; Fan Yang; Jie Xu; Dekai Qiu; Jingyuan Fang; Scott Friedman; Ruqi Tang; M Eric Gershwin; Xiong Ma
Journal:  J Autoimmun       Date:  2015-08-01       Impact factor: 7.094

Review 5.  Hepatic inflammation and progressive liver fibrosis in chronic liver disease.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 6.  Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models?

Authors:  Urs Christen; Edith Hintermann
Journal:  Int J Mol Sci       Date:  2016-12-01       Impact factor: 5.923

7.  In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT.

Authors:  Niklas Verloh; Ingo Einspieler; Kirsten Utpatel; Karin Menhart; Stefan Brunner; Frank Hofheinz; Jörg van den Hoff; Philipp Wiggermann; Matthias Evert; Christian Stroszczynski; Dirk Hellwig; Jirka Grosse
Journal:  EJNMMI Res       Date:  2018-11-09       Impact factor: 3.138

8.  Influence of hepatic fibrosis and inflammation: Correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging.

Authors:  N Verloh; U Probst; K Utpatel; F Zeman; F Brennfleck; J M Werner; C Fellner; C Stroszczynski; M Evert; P Wiggermann; M Haimerl
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

9.  The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.

Authors:  Han Wang; Xinxia Feng; Ping Han; Yu Lei; Yujia Xia; Dean Tian; Wei Yan
Journal:  Mol Med Rep       Date:  2019-10-16       Impact factor: 2.952

Review 10.  Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.

Authors:  Claudia Sirbe; Gelu Simu; Iulia Szabo; Alina Grama; Tudor Lucian Pop
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.